1
|
Almenar D, Mayans J, Juan O, Bueno JMG, Lopez JIJ, Frau A, Guinot M, Cerezuela P, Buscalla EG, Gasquet JA, Sanchez J. Pegfilgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain--results of the LEARN Study. Eur J Cancer Care (Engl) 2008; 18:280-6. [PMID: 19076208 PMCID: PMC2702003 DOI: 10.1111/j.1365-2354.2008.00959.x] [Citation(s) in RCA: 49] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Daily granulocyte colony-stimulating factors [(G-CSFs); e.g. filgrastim, lenograstim] are frequently used to reduce the duration of chemotherapy-induced neutropenia (CIN) and the incidence of febrile neutropenia (FN) in cancer patients. A pegylated formulation of filgrastim, pegfilgrastim, which is administered once per cycle, was introduced in Spain in 2003. LEARN was a multi-centre, retrospective, observational study in Spain comparing patterns of use of daily G-CSF and pegfilgrastim, and CIN-related outcomes in adults with non-myeloid malignancies receiving myelosuppressive chemotherapy. Outcome measures were the percentage of patients receiving G-CSF for primary prophylaxis versus secondary prophylaxis/treatment, duration of treatment with G-CSF and incidence of CIN-related complications. Medical records from consecutive patients with documented pegfilgrastim (n = 75) or daily G-CSF (n = 111) use during 2003 were included. The proportion of patients receiving primary or secondary prophylaxis was comparable between the pegfilgrastim (39 and 48% respectively) and daily G-CSF (40 and 48% respectively) groups. However, there was a trend towards less frequent use to treat a neutropenic event such as FN or neutropenia in the pegfilgrastim group (17 versus 30% with daily G-CSF). Chemotherapy-induced neutropenia-related complications were less frequent in patients receiving pegfilgrastim (e.g. FN 11 versus 24% with daily G-CSF). This is the first study to show the potential benefits of pegfilgrastim over daily G-CSF in Spanish clinical practice.
Collapse
Affiliation(s)
- D Almenar
- Department of Oncology, Hospital Universitario Dr Peset, Valencia, Spain.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
2
|
Perez Manga G, Garcia Bueno JM, Palombo H, Morales S, Méndez M, Esteban B. A phase II study of vinorelbine (VNR) and letrozole (LTZ) in aged women with metastatic breast cancer (MBC). J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.756] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- G. Perez Manga
- Hospital Gregorio Marañon, Madrid, Spain; Clinica Miramar, Palma de Mallorca, Spain; Clinica Remei, Barcelona, Spain; Hospital Arnau de Vilanova, Lerida, Spain; Hospital de Móstoles, Madrid, Spain; Hospital General de Segovia, Segovia, Spain
| | - J. M. Garcia Bueno
- Hospital Gregorio Marañon, Madrid, Spain; Clinica Miramar, Palma de Mallorca, Spain; Clinica Remei, Barcelona, Spain; Hospital Arnau de Vilanova, Lerida, Spain; Hospital de Móstoles, Madrid, Spain; Hospital General de Segovia, Segovia, Spain
| | - H. Palombo
- Hospital Gregorio Marañon, Madrid, Spain; Clinica Miramar, Palma de Mallorca, Spain; Clinica Remei, Barcelona, Spain; Hospital Arnau de Vilanova, Lerida, Spain; Hospital de Móstoles, Madrid, Spain; Hospital General de Segovia, Segovia, Spain
| | - S. Morales
- Hospital Gregorio Marañon, Madrid, Spain; Clinica Miramar, Palma de Mallorca, Spain; Clinica Remei, Barcelona, Spain; Hospital Arnau de Vilanova, Lerida, Spain; Hospital de Móstoles, Madrid, Spain; Hospital General de Segovia, Segovia, Spain
| | - M. Méndez
- Hospital Gregorio Marañon, Madrid, Spain; Clinica Miramar, Palma de Mallorca, Spain; Clinica Remei, Barcelona, Spain; Hospital Arnau de Vilanova, Lerida, Spain; Hospital de Móstoles, Madrid, Spain; Hospital General de Segovia, Segovia, Spain
| | - B. Esteban
- Hospital Gregorio Marañon, Madrid, Spain; Clinica Miramar, Palma de Mallorca, Spain; Clinica Remei, Barcelona, Spain; Hospital Arnau de Vilanova, Lerida, Spain; Hospital de Móstoles, Madrid, Spain; Hospital General de Segovia, Segovia, Spain
| |
Collapse
|